In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
KCCYSL peptide was synthesized with the chelates diaminopropionc acid (DAP), Nα-histidinyl acetic acid [(NαHis)Ac], and 4-Ala-1,2-3-Triazol-1-acetic acid [(Ala-Triazol)Ac] at its amino-terminus via a gly-ser-gly (GSG) spacer and radiolabeled with [99mTc(H2O)3(CO)3]+. Radiolabeled peptide binding to cultured human MDA-MB-435 breast carcinoma cells was examined. Biodistribution and single photon emission computed tomography (SPECT)/CT imaging of the radiolabeled peptides were evaluated in female SCID mice bearing human MDA-MB-435 breast tumors.
Results demonstrated that 99mTc(CO)3-DAP-GSG-KCCYSL, 99mTc(CO)3-(NαHis)Ac-GSG-KCCYSL and 99mTc(CO)3- (Ala-Triazol)Ac-GSG-KCCYSL were stable and bound to MDA-MB-435 cells. In vivo biodistribution studies revealed that tumor uptake of 99mTc(CO)3-DAP-GSG-KCCYSL was 1.67 ±0.16, 1.25 ±0.61, 0.88 ±0.12, 0.30 ±0.06 % ID/g at 1, 2, 4, and 24 h post injection, respectively. Tumor uptake of 99mTc(CO)3-(NαHis)Ac-GSG-KCCYSL was 0.76 ±0.13, 0.75 ±0.40, 0.33 ±0.08, 0.16 ±0.02 % ID/g at 1, 2, 4, and 24 h post injection, respectively. Tumor uptake of 99mTc(CO)3-(Ala- Triazol)Ac-GSG-KCCYSL was 1.15 ±0.12, 0.63 ±0.09, 0.30 ±0.02, 0.09 ±0.02 % ID/g at 1, 2, 4, and 24 h post injection, respectively. SPECT/CT studies showed tumor selective uptake of the peptides in the tumor-bearing mice. Specific uptake was confirmed by competitive receptor blocking studies.
99mTc(CO)3-DAP-GSG-KCCYSL and 99mTc(CO)3-(Ala-Triazol)Ac-GSG-KCCYSL may be better as imaging agents due to their higher tumor to non-target uptake ratios than 99mTc(CO)3-(NαHis)Ac-GSG-KCCYSL.
Keywords: (SPECT)/CT imaging; Azidoacetic acid; BBN analogues; Breast Carcinoma Imaging; Breast cancer; Cell Culture; Cell Lines; ErbB-2; ErbB-2-Targeting Peptides; Genzyme; HPLC; High Performance Liquid; Laemmli Buffer; Liquid Chromatography-Mass Spectrometry; N-histidinyl acetic acid [(NHis)Ac]; Novabiochem; Peptide Synthesis; Technetium-99m; Thin Layer Chromatography; [99mTc(CO)]-Radiolabeled; a gly-ser-gly (GSG); chelates diaminopropionc acid (DAP); click chemistry; diaminopropionc acid; epidermal growth factor receptor; human breast carcinoma cells; murine monoclonal antibody; peptide; pertuzumab; phenol; phosphate-buffered solution; phosphatidylinositol 3-kinase; preparative HPLC; radioimaging; single photon computed emission tomography; technetium; thioanisole; trastuzumab; tricarbonyl; trifluoroacetic acid; type 1 receptor tyrosine kinase
Document Type: Research Article
Publication date: October 1, 2010
- Current Radiopharmaceuticals publishes original research articles, letters, reviews, drug clinical trial studies and guest edited issues on all aspects of research and development of radiolabelled compound preparations. The scope of the journal covers the following areas: radio imaging techniques, therapies; preparation and application of radionuclide compounds including the incorporation of tracer methods used in scientific research and applications.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites